Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials.
Lucie Joerg, Julia Stolyar, John McGovern et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed randomized clinical trials of Bruton tyrosine kinase (BTK) inhibitors for systemic lupus erythematosus (SLE), including potential effects on cutaneous disease. Five trials met inclusion criteria, evaluating elsubrutinib, evobrutinib, fenebrutinib, and orelabrutinib. Efficacy across SLE endpoints was variable: elsubrutinib- and orelabrutinib-based regimens improved cutaneous disease, whereas evobrutinib and fenebrutinib showed limited or nonsignificant differences from placebo on primary endpoints. Safety was generally acceptable, with infections and transaminase elevations among reported adverse events. No trials specifically evaluated BTK inhibition in cutaneous lupus erythematosus (CLE).
Key findings
- Five randomized clinical trials were included, evaluating four BTK inhibitors.
- Elsubrutinib- and orelabrutinib-based regimens improved cutaneous disease.
- Evobrutinib and fenebrutinib showed limited or nonsignificant differences from placebo on primary endpoints.
- Reported adverse events included infections and transaminase elevations; overall safety was described as generally acceptable.
Why it matters
The review suggests that BTK inhibition may have activity against cutaneous manifestations of SLE, but efficacy was not consistent across agents or endpoints. The absence of trials specifically in CLE leaves uncertainty about benefit in that condition. These findings help distinguish a promising therapeutic target from an established treatment approach.
What to keep in mind
Only five randomized trials were included, and efficacy findings varied across agents and endpoints. No included trial evaluated BTK inhibition specifically in CLE.